Table 2 Univariate survival analysis of 245 patients with breast cancer treated with surgery followed by anthracycline‐based adjuvant chemotherapy.
| Parameter | n | Events | MFS Mean (SD) | p value (log rank test) | Events | OS Mean (SD) | p value (log rank test) |
|---|---|---|---|---|---|---|---|
| Size | <0.005 | >0.1000 | |||||
| T1 | 127 | 19 | 118 (3.68) | 20 | 115.4 (4.09) | ||
| T2 | 100 | 22 | 110 (4.72) | 18 | 114.9 (4.35) | ||
| T3 | 16 | 8 | 59 (7.40) | 4 | 76.4 (7.47) | ||
| Grade | <0.1000 | <0.1000 | |||||
| I | 23 | 1 | 117 (3.94) | 1 | 117 (3.64) | ||
| II | 69 | 11 | 118 (4.83) | 8 | 121 (4.93) | ||
| III | 148 | 37 | 407 (4.08) | 33 | 109 (4.00) | ||
| LN metastasis | <0.0001 | <0.0005 | |||||
| No | 83 | 5 | 129 (2.80) | 5 | 129 (2.60) | ||
| Yes | 154 | 44 | 102 (4.25) | 37 | 105 (4.32) | ||
| LVI | <0.0500 | >0.1000 | |||||
| No | 82 | 82 | 121 (4.14) | 11 | 121 (4.15) | ||
| Yes | 161 | 161 | 101 (3.66) | 31 | 104 (3.73) | ||
| ER | <0.0010 | 0.0001 | |||||
| Negative | 48 | 18 | 84 (6.78) | 17 | 86.8 (6.53) | ||
| Positive | 191 | 30 | 117 (3.11) | 24 | 119.2 (3.17) | ||
| PR | <0.0100 | <0.0005 | |||||
| Negative | 64 | 20 | 92.2 (5.96) | 20 | 92.8 (5.84) | ||
| Positive | 175 | 28 | 116.9 (3.26) | 21 | 119.7 (3.33) | ||
| HER2 | >0.1000 | >0.1000 | |||||
| Negative | 200 | 38 | 113.3 (3.25) | 32 | 115 (3.43) | ||
| Positive | 36 | 10 | 98.4 (7.84) | 9 | 102 (7.28) | ||
| EGFR | >0.1000 | <0.1000 | |||||
| Negative | 222 | 42 | 113.4 (3.08) | 35 | 115.5 (3.18) | ||
| Positive | 22 | 7 | 90.9 (9.20) | 7 | 92.3 (8.79) | ||
| Ck 14 | <0.0500 | <0.0500 | |||||
| Negative | 221 | 41 | 114.0 (3.05) | 34 | 116.0 (3.13) | ||
| Positive | 22 | 8 | 84.5 (10.13) | 8 | 86.6 (9.47) | ||
| Ck 5/6 | <0.0500 | <0.0100 | |||||
| Negative | 210 | 39 | 114.0 (3.11) | 32 | 116.2 (3.19) | ||
| Positive | 25 | 9 | 84.8 (9.47) | 9 | 86.8 (8.95) | ||
| Ck 17 | <0.0005 | <0.0001 | |||||
| Negative | 213 | 35 | 116.4 (2.97) | 28 | 118.5 (3.06) | ||
| Positive | 28 | 12 | 78.1 (9.24) | 12 | 80.3 (8.72) | ||
| p53 | <0.0500 | <0.0010 | |||||
| Negative | 158 | 25 | 117 (3.41) | 18 | 120 (3.52) | ||
| Positive | 67 | 20 | 102 (6.21) | 20 | 103 (6.06) | ||
| MIB1 | <0.0100 | <0.0050 | |||||
| <10% | 96 | 14 | 118.3 (4.22) | 11 | 122.4 (3.66) | ||
| 10–30% | 97 | 20 | 111.7 (4.86) | 16 | 111.4 (5.48) | ||
| >30% | 33 | 13 | 86.7 (8.87) | 13 | 88.8 (8.44) | ||
| MYC gene | 0.0050 | <0.0050 | |||||
| Non‐amplified | 176 | 32 | 114.2 (3.43) | 27 | 117 (3.34) | ||
| Amplified | 19 | 8 | 86.1 (12.82) | 8 | 84.4 (12.17) |
Ck, cytokeratin; ER, oestrogen receptor; LN, lymph node metastasis; LVI, lympho‐vascular invasion; MFS, metastasis‐free survival; OS, overall survival; PR, progesterone receptor.